NEU
Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.
Shorted
About
website
industry
address
Key Metrics
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Short Position Trends
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns
Industry & Focus
Company Overview
AI-generated company summary
Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.
Company History
Neuren Pharmaceuticals was founded with a mission to develop treatments for neurological disorders. Over the years, the company has evolved by focusing on research and development, leading to significant advancements in its product pipeline. Major milestones include the development of DAYBUE® (trofinetide) and NNZ-2591, which target specific syndromes such as Rett Syndrome and Phelan-McDermid Syndrome. Neuren has consistently expanded its research capabilities and partnerships to enhance its market presence.
Competitive Advantages
Neuren Pharmaceuticals has a competitive advantage in its specialized focus on neurological conditions, allowing for targeted and effective treatment development. The company's robust pipeline, including products like DAYBUE® and NNZ-2591, positions it as a leader in addressing rare neurological disorders. Additionally, Neuren's strategic partnerships and collaborations enhance its research capabilities and market reach.
Risk Factors
- •Regulatory approval challenges
- •High R&D costs
- •Market competition
Recent Developments
Last 6 months
In the past six months, Neuren Pharmaceuticals has projected DAYBUE® net sales to reach approximately US$700 million by 2028, highlighting its growth potential. The company has also published results from its NNZ-2591 Phase 2 trial in Neurology Genetics, demonstrating progress in its clinical development programs.
Key People
Leadership team at Neuren Pharmaceuticals
Richard Treagus
Executive Chairman
Richard Treagus has extensive experience in the pharmaceutical industry, having held senior executive roles in both public and private companies. He brings strategic leadership to Neuren Pharmaceuticals.
Patrick Davies
Non-Executive Director
Patrick Davies has a strong background in corporate finance and governance, contributing to Neuren's strategic direction and financial oversight.
Financial Reports
85 reports available
Showing 10 of 85 reports